ADLR Adolor Corporation featured news, full reports, and detailed charts
Adolor Corporation (ADLR) Wrap Up:
Various statements made in this Annual Report on Form 10-K are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f02%2f29%2f0001193125-08-043467.html#FIS_BUSINESS"Adolor Corp. (ADLR:NASDAQ)
Snapshot of Adolor Corp. (ADLR)
|
OPEN
$1.49
|
PREVIOUS CLOSE
$1.50
|
|
|
DAY HIGH
$1.54
|
DAY LOW
$1.49
|
|
|
52 WEEK HIGH
02/6/09 - $2.55
|
52 WEEK LOW
12/19/08 - $1.27
|
|
|
MARKET CAP
70.0M
|
AVERAGE VOLUME 3 mo
132.8K
|
|
|
DILUTED EPS TTM
$-1.21
|
SHARES OUTSTANDING
46.3M
|
|
|
ADLR Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
With the company facing billions in lost sales, its research chief is set on doing things differently
ADLR Top Compensated Officers
Executives, Board Directors
Key developments for Adolor Corp. (ADLR)
Adolor Corp. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on November 3, 2009).
Adolor Corp. reported unaudited earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported a net loss of approximately $11.1 million, or $0.24 per basic and diluted share, for the three months ended September 30, 2009 compared to a net loss of $13.3 million, or $0.29 per basic and diluted share, for the three months ended September 30, 2008. The company reported loss from operations of $11.289 million on total net revenues of $8.663 million compared to the loss from operations of $14.166 million on total net revenues of $7.870 million for the same period a year ago. For the nine months ended September 30, 2009, the Company reported a net loss of approximately $40.9 million, or $0.88 per basic and diluted share, compared to a net loss of $14.8 million, or $0.32 per basic and diluted share, for the nine months ended September 30, 2008. The prior year nine month period was favorably impacted by a $20.0 million milestone payment received from GlaxoSmithKline (GSK) in the second quarter of 2008 upon the approval of ENTEREG(R) (alvimopan) by the U.S. Food and Drug Administration. The company reported loss from operations of $41.813 million on total net revenues of $24.406 million compared to the loss from operations of $18.447 million on total net revenues of $41.045 million for the same period a year ago.
Adolor Corp., Q3 2009 Earnings Call, Oct 29 2009
ADLR Competitors
| Company | Last | Change |
| Progenics Pharmaceuticals Inc | $4.07 USD | +0.08 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ADLR | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 2.1x |
|
| Price/Book | 1.4x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
ADLR |
||
ADLR transactions
| Type Date |
Target |
|
Merger/Acquisition
September 21, 2009 |
Eli Lilly & Co., OpRA III |